Drug
N-phenylacetoaminomethylene-DL-p-nitrophenylalanine clinical trials
- studies test it
- 14
- open now
- 0
- in phase 3
- 5
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 8
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Studies
Open first, then newest update. How each study uses N-phenylacetoaminomethylene-DL-p-nitrophenylalanine is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study of A-101 for the Treatment of Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT02260180Written as A-101
- Safety Study of A-101 Topical Solution for the Treatment of Common WartsCompletedPhase 3Aclaris Therapeutics, Inc.NCT03812510Written as A-101
- Study of A-101 Topical Solution for the Treatment of Common WartsCompletedPhase 3Aclaris Therapeutics, Inc.NCT03687372Written as A-101
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa NigraCompletedPhase 2Aclaris Therapeutics, Inc.NCT03224598Written as A-101 Topical Solution 40%
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic KeratosesCompletedPhase 4Aclaris Therapeutics, Inc.NCT03487588Written as A-101 Topical Solution
- A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT03148691Written as A-101
- A Phase2 of A-101 Topical Solution in Subjects With Common WartsCompletedPhase 2Aclaris Therapeutics, Inc.NCT03210337Written as A-101 Topical Solution
- A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common WartsCompletedPhase 2Aclaris Therapeutics, Inc.NCT03278028Written as A-101 Topical Solution
- Dose-Response Profile of A-101 in Subjects With Seborrheic KeratosisCompletedPhase 2Aclaris Therapeutics, Inc.NCT02160626Written as A-101 (40) Topical Solution
- Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic KeratosisCompletedPhase 1/2Aclaris Therapeutics, Inc.NCT01986920Written as A-101 25%
- A Study of A-101 Solution in Subjects With Common Warts.CompletedPhase 2Aclaris Therapeutics, Inc.NCT02669862Written as A-101 Solution 40
- An Open-Label Safety Study of A-101 SolutionCompletedPhase 3Aclaris Therapeutics, Inc.NCT02667288Written as A-101 Solution
- A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.CompletedPhase 3Aclaris Therapeutics, Inc.NCT02667236Written as A-101 Solution
- A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic KeratosisCompletedPhase 3Aclaris Therapeutics, Inc.NCT02667275Written as A-101 Solution